Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
42 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Review, H2 2016', provides in depth analysis on Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted pipeline therapeutics. The report provides comprehensive information on the Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - The report reviews Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics and enlists all their major and minor projects - The report assesses Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) Overview 6 Therapeutics Development 7 Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Stage of Development 7 Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Therapy Area 8 Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Indication 9 Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Products under Development by Companies 12 Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Companies Involved in Therapeutics Development 20 Crescendo Biologics Limited 20 Exicure, Inc. 21 Novartis AG 22 Teva Pharmaceutical Industries Ltd. 23 UCB S.A. 24 Vipergen ApS 25 Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Drug Profiles 26 Antisense Oligonucleotide to Antagonize IL-17RA for Inflammatory Disorders - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 bimekizumab - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 CB-001 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 E-34935 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 E-35018 - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 E-35762 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 E-36041 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 Recombinant Protein to Inhibit IL-17A for Psoriasis - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Small Molecules to Antagonize IL-17A for Inflammatory and Autoimmune Diseases - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Dormant Projects 36 Interleukin 17 Receptor A (CDw217 or CD217 or IL17RA) - Featured News & Press Releases 37 Jun 10, 2016: UCB's bimekizumab demonstrates positive results in early development in patients with psoriatic arthritis 37 Jun 08, 2016: UCB presents Phase 1b data on Bimekizumab at the Annual European Congress of Rheumatology (EULAR 2016) 38 Sep 01, 2013: Vipergen presents first discovery of small molecule IL-17A antagonists 38 Apr 01, 2013: Ensemble Therapeutics To Present Preclinical Data On IL-17A Inhibitors At 245th ACS National Meeting 39 Nov 12, 2012: Ensemble Therapeutics Presents Oral Efficacy Of Small Molecule Targeting IL-17 For Inflammation In Preclinical Studies 39 Oct 29, 2012: Ensemble Therapeutics To Present Poster On Interleukin-17 At 2012 ACR Annual Meeting 40 Appendix 41 Methodology 41 Coverage 41 Secondary Research 41 Primary Research 41 Expert Panel Validation 41 Contact Us 41 Disclaimer 42
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Assessment by Monotherapy/Combination Products, H2 2016 14 Number of Products by Stage and Mechanism of Action, H2 2016 15 Number of Products by Stage and Route of Administration, H2 2016 17 Number of Products by Stage and Molecule Type, H2 2016 19 Pipeline by Crescendo Biologics Limited, H2 2016 20 Pipeline by Exicure, Inc., H2 2016 21 Pipeline by Novartis AG, H2 2016 22 Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 23 Pipeline by UCB S.A., H2 2016 24 Pipeline by Vipergen ApS, H2 2016 25 Dormant Projects, H2 2016 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
